Welcome to our dedicated page for Senti Biosciences Holdings SEC filings (Ticker: SNTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senti Biosciences SEC filings document a clinical-stage biotechnology issuer built around the Gene Circuit platform and its cell-therapy pipeline. The company’s 8-K reports cover operating and financial results, corporate updates, clinical or regulatory disclosures, shareholder voting matters, governance items, capital-structure matters and material agreements, including research-and-development laboratory lease disclosures.
The filing record also includes a Form 15-12G for Senti Biosciences, Inc. after a completed Delaware holding company reorganization under which Senti became a subsidiary within Senti Biosciences Holdings. That filing addresses termination or suspension of Exchange Act registration and reporting duties for the covered Senti common stock, alongside the issuer’s corporate-status and security-class disclosures.
Senti Biosciences (SNTI) – Form 4 filing overview
Director Edward T. Mathers reported a single transaction dated 06/25/2025 involving the award of 21,950 non-qualified stock options on SNTI common shares.
- Exercise price: $2.05 per share
- Expiration: 06/24/2035 (10-year term)
- Vesting schedule: 100% of the options vest on the earlier of (i) the first anniversary of the grant or (ii) the 2026 Annual Meeting, contingent on continued board service.
- Post-transaction holdings: 21,950 derivative securities held directly; no common shares were bought or sold.
The filing reflects routine director compensation rather than an open-market purchase or sale, so there is no immediate cash outflow for the insider and no change to the public float until potential future exercise. The $2.05 strike price indicates the board’s view of current fair value; it also sets a performance hurdle that could align the director’s long-term incentives with shareholder returns.